MIIP and neoplasm: However, the combined therapy (oxaliplatin + SR59230A or SSO) significantly suppressed tumor growth in MIIP-downregulated tumors, resulting in markedly reduced average tumor size and weight compared to oxaliplatin alone treatment and scramble tumors (Fig. 7b–d).